- Home
- MPV vs CHRS Comparison
MPV vs CHRS Comparison
Compare MPV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- CHRS
- Stock Information
- Founded
- MPV 1988
- CHRS 2010
- Country
- MPV United States
- CHRS United States
- Employees
- MPV N/A
- CHRS 235
- Industry
- MPV Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPV Finance
- CHRS Health Care
- Exchange
- MPV Nasdaq
- CHRS Nasdaq
- Market Cap
- MPV 181.3M
- CHRS 134.4M
- IPO Year
- MPV N/A
- CHRS 2014
- Fundamental
- Price
- MPV $16.91
- CHRS $1.16
- Analyst Decision
- MPV
- CHRS Strong Buy
- Analyst Count
- MPV 0
- CHRS 4
- Target Price
- MPV N/A
- CHRS $5.38
- AVG Volume (30 Days)
- MPV 25.2K
- CHRS 2.4M
- Earning Date
- MPV 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- MPV 8.71%
- CHRS N/A
- EPS Growth
- MPV N/A
- CHRS N/A
- EPS
- MPV 1.71
- CHRS N/A
- Revenue
- MPV N/A
- CHRS $304,340,000.00
- Revenue This Year
- MPV N/A
- CHRS $2.47
- Revenue Next Year
- MPV N/A
- CHRS N/A
- P/E Ratio
- MPV $9.35
- CHRS N/A
- Revenue Growth
- MPV N/A
- CHRS 44.19
- 52 Week Low
- MPV $11.18
- CHRS $0.66
- 52 Week High
- MPV $16.42
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- MPV 55.53
- CHRS 38.01
- Support Level
- MPV $16.00
- CHRS $1.03
- Resistance Level
- MPV $17.20
- CHRS $1.39
- Average True Range (ATR)
- MPV 0.43
- CHRS 0.14
- MACD
- MPV 0.05
- CHRS -0.03
- Stochastic Oscillator
- MPV 61.08
- CHRS 14.04
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.